MAPKAPK2 and autoimmune disease: MK2 inhibitor drugs have undergone early clinical trials for pulmonary and autoimmune diseases with few reported side effects [48,49,50], suggesting that they are promising new treatment approaches that should be further investigated [1,2,3].